IP Library Granted Patent US 9,000,028
Granted Patent B2
US 9,000,028 · App. 13/859,581 · Granted Apr 7, 2015

Indole and indazole compounds as an inhibitor of cellular necrosis

Inventors: Soon Ha Kim (Daejeon, KR); Hyoung Jin Kim (Daejeon, KR); Sun Young Koo (Daejeon, KR); Chul Woong Chung (Daejeon, KR); Sung Bae Lee (Daejeon, KR); Heui Sul Park (Daejeon, KR); Seung Hyun Yoon (Daejeon, KR); Hyo Shin Kwak (Daejeon, KR); Dong Ook Seo (Daejeong, KR); Eok Park (Daejeong, KR)
Assignee: LG Life Sciences Ltd.
C07D417/06C07D413/04C07D413/14C07D417/04C07D417/14C07D487/04C07F9/65586A61K31/404A61K31/416A61K31/427A61K31/4439A61K31/454A61K31/4545A61K31/496A61K31/497A61K31/5377A61K31/541A61K45/06A61K31/445A61K31/675C07F9/65583
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,000,028
App. No.
13/859,581
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.

Claims (34)

1. A method of inhibiting necrosis in tissue selected from the group consisting of liver, pancreas and cartilage, comprising: administering an effective amount of a compound of formula (1) or pharmaceutically acceptable salt or enantiomer or diastereomer thereof to a subject in need thereof, wherein the compound is an indole compound of the following formula (1):

in which

n denotes a number of 1 to 3,

m denotes 0 or 1,

A represents phenyl,

X represents C or CH, with the proviso that m is 1 when X is C,

R 1 represent hydrogen, alkyl, —(CH 2 ) r NR 7 R 8 , or —(CH 2 ) r CO 2 H, wherein r denotes a number of 1 to 5, and R 7 and R 8 independently of one another represent hydrogen, alkyl or alkylcarbonyl, or may together form an optionally alkyl-substituted alkylene chain wherein optionally one methylene is replaced by N atom,

R 2 represents hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkoxy or trialkylsilyl, represents —(CH 2 ) p CO 2 R 7 , —(CH 2 ) p OR 7 , —(CH 2 ) p NR 7 R 8 , —NHR 10 , —N(H)S(O) 2 R 7 , —NHC(O)R 10 , —(CH 2 ) p S(O) 2 R 7 or (CH 2 ) p -heterocycle-R 10 , wherein p denotes a number of 0 to 3, R 7 and R 8 are as defined above, R 10 represents hydrogen, oxo, alkylsulfonyl, alkylcarbonyl, alkyloxycarbonyl, alkylaminocarbonyl, alkoxy, alkyl or heterocycle,

R 3 represents hydrogen, cyano, halogen, alkyl or phenyl, or represents —(CH 2 ) n -heterocycle or —(CH 2 ) n -aryl, wherein n denotes a number of 0 to 3,

R 4 represents —YR 11 , wherein Y represents a direct bond or —(CR 7 R 8 ) p Y′—, wherein p denotes a number of 0 to 3, R 7 and R 8 are as defined above, Y′ is selected from the group consisting of —O—, —S—, —NR 12 —, —NR 12 C(O)—, —C(O)—, —C(O)O—, —C(O)NR 12 —, —S(O) q —, and —S(O) q NR 12 —, wherein R 12 represents hydrogen, alkyl, aryl or heteroaryl, q denotes a number of 0 to 2, R 11 is selected from the group consisting of hydrogen, cyano, halogen, hydroxy, thiol, carboxy, alkyl and —(CH 2 ) t B—R 13 , wherein t denotes a number of 0 to 3, B represents heterocycle, heteroaryl or aryl, R 13 represents hydrogen, cyano, halogen, hydroxy, oxo, thiol, carboxy, carboxyalkyl, alkylcarbonyloxy, alkyl, alkoxy, alkylthio, alkylcarbonyl or alkylsulfonyl,

R 5 represents hydrogen, alkyl, cycloalkyl, heterocycle or heterocyclylalkyl,

R 6 represents —(CR 7 R 8 ) p —Z-D-W—R 14 , wherein Z represents a direct bond, or is selected from the group consisting of —C(O)—, —C(O)O—, —C(O)NR 12 —, and —S(O) y —, y denotes a number of 1 or 2, D represents a direct bond, or represents cycloalkyl, heteroaryl or heterocycle, W represents a direct bond, or represents —NR 7 —, —C(O)—, —C(O)O—, —C(O)NR 12 —, —S(O) y —, —S(O) y NR 12 — or —NR 12 S(O) y —, wherein R 14 represents hydrogen, hydroxy, alkyl, alkoxy, heterocycle, heteroaryl, aryl or aralkyl,

R 5 and R 6 together represent alkylene chain,

where alkyl, alkoxy, aryl, cycloalkyl, heterocycle and heteroaryl may be optionally substituted, and the substituents are one or more selected from the group consisting of hydroxy, halogen, nitrile, amino, alkylamino, dialkylamino, carboxy, alkyl, alkoxy, carboxyalkyl, alkylcarbonyloxy, alkylthio, alkyloxycarbonyl, alkylaminocarbonyl, arylalkoxy and oxo,

provided that R 3 is phenyl when X is CH, and

provided that R 6 is not hydrogen when X is C,

and pharmaceutically acceptable salts or enantiomers or diasteromers thereof.

2. The method of claim 1 , wherein the tissue is liver tissue.

3. A method of inhibiting necrosis in a cell, comprising: contacting a compound with the cell, wherein the compound is an indole compound having the following formula (1):

in which

n denotes a number of 1 to 3,

m denotes 0 or 1,

A represents phenyl,

X represents C or CH, with the proviso that m is 1 when X is C,

R 1 represent hydrogen, alkyl, —(CH 2 ) r NR 7 R 8 , or —(CH 2 ) r CO 2 H, wherein r denotes a number of 1 to 5, and R 7 and R 8 independently of one another represent hydrogen, alkyl or alkylcarbonyl, or may together form an optionally alkyl-substituted alkylene chain wherein optionally one methylene is replaced by N atom,

R 2 represents hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkoxy or trialkylsilyl, represents —(CH 2 ) p CO 2 R 7 , —(CH 2 ) p OR 7 , —(CH 2 ) p NR 7 R 8 , —NHR 10 , —N(H)S(O) 2 R 7 , —NHC(O)R 10 , —(CH 2 ) p S(O) 2 R 7 or (CH 2 ) p -heterocycle-R 10 , wherein p denotes a number of 0 to 3, R 7 and R 8 are as defined above, R 10 represents hydrogen, oxo, alkylsulfonyl, alkylcarbonyl, alkyloxycarbonyl, alkylaminocarbonyl, alkoxy, alkyl or heterocycle,

R 3 represents hydrogen, cyano, halogen, alkyl or phenyl, or represents —(CH 2 ) n -heterocycle or —(CH 2 ) n -aryl, wherein n denotes a number of 0 to 3,

R 4 represents —YR 11 , wherein Y represents a direct bond or —(CR 7 R 8 ) p Y′—, wherein p denotes a number of 0 to 3, R 7 and R 8 are as defined above, Y′ is selected from the group consisting of —O—, —S—, —NR 12 C(O)—, —C(O)—, —C(O)O—, —C(O)NR 12 —, —S(O) q —, and —S(O) q NR 12 —, wherein R 12 represents hydrogen, alkyl, aryl or heteroaryl, q denotes a number of 0 to 2, R 11 is selected from the group consisting of hydrogen, cyano, halogen, hydroxy, thiol, carboxy, alkyl and —(CH 2 ) t B—R 13 , wherein t denotes a number of 0 to 3, B represents heterocycle, heteroaryl or aryl, R 13 represents hydrogen, cyano, halogen, hydroxy, oxo, thiol, carboxy, carboxyalkyl, alkylcarbonyloxy, alkyl, alkoxy, alkylthio, alkylcarbonyl or alkylsulfonyl,

R 5 represents hydrogen, alkyl, cycloalkyl, heterocycle or heterocyclylalkyl,

R 6 represents —(CR 7 R 8 ) p —Z-D-W—R 14 , wherein Z represents a direct bond, or is selected from the group consisting of —C(O)—, —C(O)O—, —C(O)NR 12 —, and —S(O) y —, y denotes a number of 1 or 2, D represents a direct bond, or represents cycloalkyl, heteroaryl or heterocycle, W represents a direct bond, or represents —NR 7 —, —C(O)—, —C(O)O—, —C(O)NR 12 —, S(O) y —, —S(O) y NR 12 — or —NR 12 S(O) y —, wherein R 14 represents hydrogen, hydroxy, alkyl, alkoxy, heterocycle, heteroaryl, aryl or aralkyl,

R 5 and R 6 together represent alkylene chain,

where alkyl, alkoxy, aryl, cycloalkyl, heterocycle and heteroaryl may be optionally substituted, and the substituents are one or more selected from the group consisting of hydroxy, halogen, nitrile, amino, alkylamino, dialkylamino, carboxy, alkyl, alkoxy, carboxyalkyl, alkylcarbonyloxy, alkylthio, alkyloxycarbonyl, alkylaminocarbonyl, arylalkoxy and oxo,

provided that R 3 is phenyl when X is CH, and

provided that R 6 is not hydrogen when X is C.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 13305857 PREVIOUSLY RECORDED AT REEL: 043257 FRAME: 0247. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME . Recorded Sep 20, 2017
From: LG LIFE SCIENCES LTD.
To: LG CHEM, LTD.
Reel/Frame 043710/0909 →
MERGER Recorded Sep 2, 2017
From: LG LIFE SCIENCES LTD.
To: LG CHEM, LTD.
Reel/Frame 043475/0619 →
MERGER AND CHANGE OF NAME Recorded Aug 10, 2017
From: LG LIFE SCIENCES LTD.; LG CHEM, LTD.
To: LG CHEM, LTD.
Reel/Frame 043257/0247 →
Priority Claims (1)
KR 10-2007-00882687 · Aug 17, 2007 · national
Continuity (2)
Division 12671038 · Mar 4, 2010
Related Publication 20130237532A1 · Sep 12, 2013